5-hydroxytryptamine2A receptor inverse agonists as antipsychotics
about
sameAs
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey modelRole of the serotonin 5-HT(2A) receptor in learningAntipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanismsDistinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning.Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotectionAnimal Models of Psychosis: Current State and Future Directions.Molecular targets for treating cognitive dysfunction in schizophrenia.Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement.Chemical genomics: massively parallel technologies for rapid lead identification and target validation.Clozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a βarrestin2-independent activation of AktSerotonin at the nexus of impulsivity and cue reactivity in cocaine addiction.Differential effects of intermittent versus continuous haloperidol treatment throughout adolescence on haloperidol sensitization and social behavior in adulthoodSerotonin receptors and heart valve disease--it was meant 2B.Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs.Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists.Locomotion after spinal cord injury depends on constitutive activity in serotonin receptorsFunctional enhancement of AT1R potency in the presence of the TPαR is revealed by a comprehensive 7TM receptor co-expression screen.Motoneuron excitability and muscle spasms are regulated by 5-HT2B and 5-HT2C receptor activity.Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challengesThe alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in ratsDiscriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), ketanserin, and (R)-(+)-{alpha}-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pipidinemethanol (MDL100907) in ratsGlycogen Synthase Kinase-3 is an Intermediate Modulator of Serotonin NeurotransmissionRole of 5-HT2A receptor antagonists in the treatment of insomnia.Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs.Integrated approaches to understanding antipsychotic drug action at GPCRs.On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.New Concepts in Dopamine D2 Receptor Biased Signaling and Implications for Schizophrenia Therapy.Atypical antipsychotics and inverse agonism at 5-HT2 receptors.Signalling profile differences: paliperidone versus risperidone.Endogenous monoamine receptor activation is essential for enabling persistent sodium currents and repetitive firing in rat spinal motoneurons.Biophysical validation of serotonin 5-HT2A and 5-HT2C receptor interactionMaking Sense of Pharmacology: Inverse Agonism and Functional Selectivity
P2860
Q24646533-FDFCDE45-A82F-4CCC-A931-F7FAB9B7325BQ24685023-74F38CFA-4B43-4688-93B3-3319021D8C1AQ26745506-3F050473-38F7-4C78-868C-813E93A134F8Q30365347-8124135D-EDF5-4A44-AC27-E6B45AE821FDQ30386608-D77F3417-1EC2-45E4-B654-CFF6D4D1931AQ30410153-634B3826-8A81-4A39-9810-C69142924D92Q30491310-F2329CA2-FE6B-4964-A8A9-9016DFA2F13FQ30493133-24F11388-ADD3-48AA-912A-0630BE9DC485Q30559794-26F8788F-D28B-446B-AD7C-337413988971Q33383932-4751A5D2-709E-4C98-9B1A-B43D5E308F67Q33764262-5C8CCED8-1764-41E5-AC92-D7D8D3E41B12Q33874819-E8ABB317-CB18-4E30-9789-0FAF3F256C16Q34053684-0DD316CF-819A-4504-935D-FD0977BCB286Q34173511-107E0316-CD90-448D-8608-BCB8A3B00C02Q34236107-20B30D6F-A0C7-42A1-968D-3FBDB4C223B8Q34396223-0D5ECE83-784A-49DC-BD49-44180B4B566CQ34430446-D7AF6541-AA42-4E8F-BB10-01E0E4FBC85BQ34630128-E4D44E8C-807F-43E2-A826-313B7BAE306AQ34686451-77E1BC4D-4371-4C0B-95E0-DF4D2559163AQ36524716-286A1C9D-4E1B-4977-AC95-AFC901FB7B25Q36534965-106A4571-90EB-4FA8-817F-42B7B12D0472Q37416428-1D0275D4-F6EA-42A8-8D56-99C4C15A60C4Q37949586-37FA19B6-FDB2-41CA-B2BE-AF90C6A34D71Q38101551-01021173-7C2C-4856-9A94-8C8FA2D043F2Q38167630-7E1E8F33-9CA5-4B94-8989-C5EF053CE106Q38200335-38379E5E-F03C-480C-8ECB-6BC555CA9A25Q38200546-94529734-9B8A-41BA-80E9-84FE831B2BDDQ39004795-F64FB14F-0F9A-4A1B-BFF5-D59A1456853AQ41250110-4A57DC07-46FA-451E-A677-A0F88E5FA375Q41906281-6F857FF9-7843-4EFF-80CC-8F4FB9CDBDF2Q47148816-28DF4CA1-7C03-49F6-A8B1-D6170FC02501Q58695932-1F311E00-8C03-41A0-87F1-7A48202F8F63Q58798205-FD48A0C5-245D-48F1-BA90-39E7D67F8325
P2860
5-hydroxytryptamine2A receptor inverse agonists as antipsychotics
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
5-hydroxytryptamine2A receptor inverse agonists as antipsychotics
@ast
5-hydroxytryptamine2A receptor inverse agonists as antipsychotics
@en
5-hydroxytryptamine2A receptor inverse agonists as antipsychotics
@nl
type
label
5-hydroxytryptamine2A receptor inverse agonists as antipsychotics
@ast
5-hydroxytryptamine2A receptor inverse agonists as antipsychotics
@en
5-hydroxytryptamine2A receptor inverse agonists as antipsychotics
@nl
prefLabel
5-hydroxytryptamine2A receptor inverse agonists as antipsychotics
@ast
5-hydroxytryptamine2A receptor inverse agonists as antipsychotics
@en
5-hydroxytryptamine2A receptor inverse agonists as antipsychotics
@nl
P2093
P3181
P1476
5-hydroxytryptamine2A receptor inverse agonists as antipsychotics
@en
P2093
Andersson CM
Burstein ES
Croston GE
Currier EA
Hacksell U
P304
P3181
P407
P577
2001-10-01T00:00:00Z